查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870104

支氣管痙攣治療市場按治療方法、藥物類別、給藥途徑、通路和最終用戶分類－2025年至2032年全球預測

Bronchial Spasms Treatment Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，支氣管痙攣治療市場將成長至 4.4077 億美元，複合年成長率為 4.50%。

關鍵市場統計數據
基準年 2024 3.0972億美元
預計年份：2025年 3.2386億美元
預測年份 2032 4.4077億美元
複合年成長率 (%) 4.50%

本書權威概述了支氣管痙攣的臨床挑戰、治療方法的多樣性、患者需求以及當代治療路徑中相關人員的決策因素。

支氣管痙攣是一種陣發性但常反覆發作的下呼吸道狹窄事件，對患者和臨床診療帶來沉重負擔。其病理生理機制涉及氣道高反應性，包括平滑肌收縮、黏膜水腫和多種發炎過程，因此需要快速緩解症狀並制定預防復發的策略。臨床醫師需要在急性期治療和長期控制氣道發炎之間取得平衡，這種平衡決定了不同臨床環境下的治療選擇。因此，治療方案涵蓋了以器械為基礎的給藥系統、注射生物製藥和全身性用藥，以及針對不同作用機制的口服藥物。

精準醫療、先進的吸入平台和不斷發展的護理模式將如何重塑支氣管痙攣治療的臨床選擇和商業性路徑

近年來，治療方法和護理模式的同步發展，徹底改變了支氣管痙攣的治療方式。在治療方面，精準生物製藥和最佳化的吸入技術拓展了臨床治療手段，使針對不同表現型患者群體的個人化介入成為可能。與藥理學進步相輔相成的是，粉劑和氣霧劑給藥裝置的創新，尤其注重劑量精準、使用便利性和依從性支持，這些創新正在共同改變臨床醫生選擇和處方治療方案的方式。數位化依從性工具和遠端監測的日益普及進一步強化了這些變革，使患者能夠進行長期管理，而不僅限於間歇性就診。

評估2025年美國關稅變化對支氣管痙攣治療的供應鏈、製造業經濟、籌資策略和臨床連續性的實際影響

2025年美國關稅調整的累積影響已對支氣管痙攣治療生態系統中的相關人員產生了實際影響。由於關稅上漲，原料藥、計量閥和特殊聚合物等醫療設備組件以及進口生產設備的成本增加，給生產經濟效益帶來了上行壓力。為此，贊助商和契約製造正採取措施降低貿易政策波動帶來的風險，例如重新評估供應商協議、加速雙重採購策略，以及在某些情況下將關鍵組裝業務遷至更靠近主要市場的地方。

詳細的細分分析將治療方法、劑型、藥物類別、通路和臨床環境與臨床應用和商業化的促進因素聯繫起來

透過對治療方法、藥物類別、給藥途徑、分銷管道和最終用戶進行詳細的細分分析，重點關注治療創新與商業性機會的交匯點。不同類型的治療方法呈現出複雜的格局，吸入、注射和口服藥物各自發揮不同的作用。在吸入療法中，乾粉吸入器、定量噴霧吸入器和霧化器各自提供不同的給藥方案。乾粉吸入器分為多次使用和一次性使用兩種類型，而霧化器則分為噴射式、網式和超音波技術。注射藥物包括氨茶鹼、生物製藥和全身性糖皮質激素，其中生物製藥又細分為美泊利單抗、Omalizumab和瑞利珠單抗等藥物。口服藥物包括抗膽鹼能藥物、支氣管擴張劑、聯合治療和皮質類固醇。抗膽鹼能藥物分為長效和短效，支氣管擴張劑分為長效BETA受體激動劑和短效BETA受體激動劑，皮質類固醇有吸入劑和全身用藥兩種劑型。

美洲、歐洲、中東和非洲以及亞太地區在監管、支付方和基礎設施方面的差異將如何影響普及趨勢和存取策略

區域趨勢對全球支氣管痙攣藥物的採納、報銷和臨床應用有顯著影響。在美洲，支付方的積極參與、注重降低住院率的療效導向以及先進吸入裝置的廣泛應用，往往是推動臨床應用的主要因素。該地區的市場進入策略通常優先考慮可靠的真實世界證據，並加強對呼吸系統科醫生和基層醫療網路的相關人員教育。在歐洲、中東和非洲，監管的多樣性和報銷體系的不均衡造成了多種多樣的准入途徑，而區域性的衛生技術評估要求和採購慣例要求制定客製化化的證據文件和彈性價格設定策略。同時，在亞太地區，數位醫療的快速普及、對本土生產能力的日益重視以及支付方成熟度的差異，正在影響著給藥途徑和配銷通路的選擇，其中在線藥房和居家醫療服務在某些市場正迅速發展。

對醫藥、醫療設備和數位市場新參與企業的競爭分析表明，協作、證據生成和生產敏捷性是其差異化優勢。

支氣管痙攣治療領域的競爭格局錯綜複雜，既有老牌製藥和醫療設備公司，也有新興的專業研發公司，以及數量不斷成長的數位醫療參與企業。擁有廣泛呼吸系統產品組合的現有公司往往憑藉其在製劑研發、醫療設備設計和全球分銷網路方面的綜合能力來維持市場地位。同時，規模較小的專業公司則專注於新型作用機制和差異化給藥技術，從而佔據了利基市場。醫療設備開發商和生物製藥開發商之間的合作日益密切，致力於開發旨在提高患者用藥依從性和改善臨床療效的聯合解決方案。

針對製造商和供應商的具體策略行動，旨在加強供應韌性、促進合規性、產生令人信服的真實世界證據並加快獲取途徑。

產業領導者應優先考慮兼顧臨床價值和商業性韌性的實際措施。首先，應實現關鍵零件和原料籌資策略的多元化，以降低關稅和地緣政治干擾帶來的風險，同時評估近岸外包和雙重採購機會，以縮短前置作業時間。其次，應投資於醫療設備的易用性和依從性工具，將客觀的依從性測量和病患教育融入產品中，以改善治療效果並提高支付方的接受度。第三，應制定嚴謹的真實世界證據產生計劃，以獲取符合支付方要求的具有臨床意義的終點指標和衛生經濟學結果，從而促進獲得有利的准入決策。

一種透明且多方面的調查方法，結合了臨床醫生的見解、文獻綜述和交叉檢驗分析，從而得出嚴謹的產業洞察。

本分析的調查方法結合了定性和定量技術，以確保對臨床實踐、醫療設備應用、支付方行為和供應動態進行多方面且平衡的分析。主要研究包括對呼吸系統科醫生、呼吸科護理師、採購人員和報銷專家進行結構化訪談，以收集他們對治療選擇、設備易用性和獲取障礙的本地觀點。次要證據來自同行評審的臨床文獻、監管指導文件、醫療設備性能規範和已發布的臨床指南，以闡明主要研究結果並檢驗基於機制的合理性。

簡明扼要地總結了治療方法、營運和政策趨勢，重點是將創新轉化為臨床影響和商業性成功的策略重點。

摘要，支氣管痙攣的治療正在經歷重大變革，這主要得益於標靶治療、給藥技術和醫療服務模式的進步。這些變革為改善患者預後創造了機遇，例如更精準的治療方法與表現型匹配、透過先進的吸入和霧化系統實現可靠的給藥，以及加強依從性監測。同時，貿易政策變化和區域監管差異等宏觀因素迫使企業在生產、採購和打入市場策略更加深思熟慮。那些能夠將臨床創新與營運韌性以及符合支付方期望的循證實踐相結合的機構將取得最大的成功。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 針對支氣管痙攣發炎路徑的生物製藥療法（例如單株抗體）發展迅速
  • 增加長效毒蕈鹼受體拮抗劑的使用，以改善慢性阻塞性氣道疾病的支氣管平滑肌鬆弛。
  • 採用具有依從性監測和即時回饋功能的數位吸入器來最佳化支氣管痙攣控制
  • 擴大吸入雙效支氣管擴張劑和皮質類固醇聯合療法的應用範圍，以減少支氣管痙攣性疾病的急性發作。
  • 急診室擴大使用霧化硫酸鎂治療急性支氣管痙攣（仿單標示外）。
  • 開發一種新型的基於奈米顆粒的氣溶膠遞送系統，用於支氣管痙攣的靶向支氣管擴張劑治療
  • 老年患者對具有更高安全性和耐受性的個人化支氣管痙攣治療的需求日益成長
  • 監管部門核准加速新一代生物製藥在嚴重、難治性氣喘相關支氣管痙攣的應用
  • 遠端醫療平台對服務不足地區慢性支氣管痙攣患者遠距監測和管理的影響
  • 利用基於生物標記的精準醫療方法，客製化支氣管痙攣治療方法

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依治療類型分類的支氣管痙攣治療市場

  • 吸入療法
    • 乾粉吸入器
      • 多劑量乾粉吸入器
      • 單劑量乾粉吸入器
    • 定量噴霧吸入器
    • 噴霧器
      • 噴射式霧化器
      • 篩孔式噴霧器
      • 超音波霧化器
  • 注射藥物
    • 氨茶鹼
    • 生物製藥
      • 美泊利單抗
      • Omalizumab
      • 瑞利珠單抗
    • 全身性皮質類固醇
  • 口服藥物
    • 抗膽鹼能藥物
      • 長效抗膽鹼能藥物
      • 短效抗膽鹼能藥物
    • 支氣管擴張劑
      • 長效BETA2受體激動劑
      • 短效BETA2受體激動劑
    • 聯合治療
    • 皮質類固醇
      • 吸入性皮質類固醇
      • 全身性皮質類固醇

9. 按藥物類別分類的支氣管痙攣治療市場

  • 抗膽鹼能藥物
    • 長效抗膽鹼能藥物
    • 短效抗膽鹼能藥物
  • BETA-激動劑
    • 長效BETA2受體激動劑
    • 短效BETA2受體激動劑
  • 皮質類固醇
    • 吸入性皮質類固醇
    • 全身性皮質類固醇
  • 白三烯調節劑
    • Montelukast
    • 札菲爾庫斯特
    • 吉留頓

第10章 按給藥途徑分類的支氣管痙攣治療市場

  • 吸入
    • 氣霧劑
    • 乾粉
    • 霧化
  • 注射
    • 肌肉內注射
    • 靜脈注射
    • 皮下注射
  • 口服
    • 膠囊
    • 糖漿
    • 藥片
  • 經皮
    • 凝膠
    • 修補

第11章 支氣管痙攣治療市場（依通路分類）

  • 診所
    • 門診部
    • 專科診所
  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 網路藥房
    • 混合
    • 純線上銷售
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第12章 支氣管痙攣治療市場（依最終使用者分類）

  • 門診手術中心
  • 診所
    • 門診部
    • 專科診所
  • 居家醫療
  • 醫院
    • 私立醫院
    • 公立醫院

第13章 各地區支氣管痙攣治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 支氣管痙攣治療市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國支氣管痙攣治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GlaxoSmithKline plc
    • AstraZeneca plc
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • Merck & Co., Inc.
    • Viatris Inc.
    • Cipla Limited
    • Sumitomo Pharma Co., Ltd.
Product Code: MRR-3204321AF1B0

The Bronchial Spasms Treatment Market is projected to grow by USD 440.77 million at a CAGR of 4.50% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 309.72 million
Estimated Year [2025] USD 323.86 million
Forecast Year [2032] USD 440.77 million
CAGR (%) 4.50%

An authoritative overview of bronchial spasm clinical imperatives, therapeutic diversity, patient needs, and stakeholder decision drivers in modern care pathways

Bronchial spasms are episodic but frequently recurrent constrictive events of the lower airways that impose significant clinical burden on patients and clinical pathways. The pathophysiology involves hyperreactive airways with smooth muscle constriction, mucosal edema, and variable inflammatory processes that require rapid symptom relief as well as strategies to prevent recurrence. Clinicians balance acute management with long-term modulation of airway inflammation, and this balance shapes therapeutic choices across numerous care settings. As a result, the treatment landscape includes device-based delivery systems, injectable biologics and systemic agents, and oral therapies that address different mechanistic targets.

Against this clinical backdrop, stakeholders must navigate device usability, adherence dynamics, regulatory expectations, and evolving reimbursement environments that influence product adoption. Patients increasingly demand treatments that minimize exacerbation risk while preserving quality of life, and payers prioritize therapies that reduce hospital encounters and downstream costs. Consequently, industry participants are under pressure to demonstrate real-world effectiveness, patient-centered design, and cost-effectiveness in order to secure favorable uptake across ambulatory clinics, hospital systems, and home-care settings. This introduction frames the subsequent sections by highlighting the intersection of clinical need, therapeutic diversity, and commercial imperatives.

How precision therapeutics, advanced inhalation platforms, and care model evolution are reshaping clinical choices and commercial pathways for bronchial spasm management

Recent years have seen transformative shifts in bronchial spasms treatment driven by simultaneous advances in therapeutic modalities and care delivery models. On the therapeutic front, precise biologic agents and optimized inhalation technologies have broadened the clinical toolkit, allowing more tailored interventions for phenotypically distinct patient cohorts. Complementing pharmacologic progress, device innovation in powder and aerosol delivery has emphasized dosing accuracy, ease of use, and adherence support, which together are shifting how clinicians select and prescribe therapies. These changes are amplified by greater integration of digital adherence tools and remote monitoring, enabling longitudinal patient management beyond episodic clinic encounters.

Regulatory and reimbursement environments have evolved in parallel, with payers increasingly requesting robust real-world evidence and value-based outcomes that demonstrate reductions in acute care utilization. Meanwhile, supply chain resilience and manufacturing agility have gained prominence due to prior disruptions, prompting sponsors to diversify sourcing and localize critical components. In sum, the landscape is moving toward personalized, evidence-driven care pathways that couple targeted therapies with advanced delivery systems and data-rich performance measurement, reshaping clinical practice and commercial strategies alike.

Assessment of the practical effects of 2025 United States tariff changes on supply chains, manufacturing economics, procurement strategies, and clinical continuity for bronchial spasm treatments

The cumulative effects of the United States tariff adjustments implemented in 2025 have introduced practical implications for participants across the bronchial spasms treatment ecosystem. Tariff-driven increases in the cost of active pharmaceutical ingredients, device components such as metering valves and specialized polymers, and imported manufacturing equipment have exerted upward pressure on production economics. Sponsors and contract manufacturers have responded by re-examining supplier contracts, accelerating dual-sourcing strategies, and in some cases relocating critical assembly steps closer to key markets to mitigate exposure to trade policy volatility.

Beyond direct cost impacts, tariffs have influenced strategic prioritization of capital expenditure, with manufacturers weighing the returns of investing in localized production against the benefits of maintaining globalized supply chains. Payers and providers have also felt secondary effects; procurement negotiations now factor in longer lead times and potential price variability, which can affect formulary positioning and purchasing cadence. Looking forward, the industry is adapting through a combination of contractual hedging, increased inventory buffers for critical components, and collaborative engagements with logistics partners to preserve continuity of care without compromising regulatory compliance or clinical quality standards.

In-depth segmentation analysis linking therapeutic modalities, delivery formats, drug classes, channels, and care settings to clinical adoption and commercialization levers

A granular segmentation lens clarifies where therapeutic innovation and commercial opportunity intersect across treatment types, drug classes, administration routes, distribution channels, and end users. Examining treatment type reveals a multi-modal landscape in which inhalation therapy, injectable medications, and oral medications play distinct roles. Within inhalation therapy, dry powder inhalers, metered dose inhalers, and nebulizers represent differentiated delivery profiles; dry powder devices subdivide into multi-dose and single-dose formats, while nebulizers split into jet, mesh, and ultrasonic technologies. Injectable options include aminophylline, biologics, and systemic steroids, with biologics further differentiated by agents such as mepolizumab, omalizumab, and reslizumab. Oral medications encompass anticholinergics, bronchodilators, combination therapies, and corticosteroids, with anticholinergics separating into long-acting and short-acting variants and bronchodilators into long-acting and short-acting beta agonists, while corticosteroids appear as inhaled and systemic formulations.

When viewed by drug class, distinctions among anticholinergics, beta agonists, corticosteroids, and leukotriene modifiers influence prescribing patterns and payer assessments, and subclasses within each category affect clinical positioning. Route of administration further refines opportunity sets: inhalation modalities span aerosol, dry powder, and nebulization approaches; injectables cover intramuscular, intravenous, and subcutaneous routes; oral therapies are delivered in capsule, syrup, or tablet formats; and transdermal options include gels and patches. Distribution channel dynamics shape access and patient experience, with clinics, hospital pharmacies, online pharmacies, and retail pharmacies each subdivided by practice type or retail model. Finally, end-user segmentation highlights distinct care settings-ambulatory surgical centers, clinics, home care, and hospitals-with outpatient and specialist clinics as key subsegments and private and public hospital distinctions that affect procurement and clinical protocols. Together, these segmentation layers inform product design, commercialization tactics, and evidence generation priorities by aligning therapeutic attributes to the operational realities of each channel and user type.

How regional regulatory, payer, and infrastructure differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape adoption dynamics and access strategies

Regional dynamics materially influence how bronchial spasms therapies are adopted, reimbursed, and integrated into clinical practice across the globe. In the Americas, clinical adoption tends to be driven by strong payer engagement, emphasis on outcomes that reduce hospital utilization, and widespread availability of advanced inhalation devices; market access strategies there typically prioritize robust real-world evidence and stakeholder education for pulmonologists and primary care networks. In Europe, Middle East & Africa, regulatory diversity and heterogeneous reimbursement systems create a mosaic of access pathways, where localized health technology assessment requirements and procurement practices necessitate tailored evidence dossiers and flexible pricing approaches. Meanwhile, in the Asia-Pacific region, rapid uptake of digital health, a growing emphasis on domestic manufacturing capability, and varied payer maturity influence both route-of-administration preferences and distribution channel choices, with online pharmacies and home-care services expanding rapidly in certain markets.

Across all regions, differences in clinician training, patient preferences, and healthcare infrastructure shape which delivery systems and therapeutic classes gain traction. These regional contrasts underscore the need for differentiated commercialization plans, adaptive clinical support programs, and supply chain footprints that align with regulatory timelines and local procurement norms. Consequently, strategic planning must incorporate region-specific evidence generation, stakeholder engagement, and logistical arrangements to ensure treatment innovations translate into measurable improvements in patient outcomes and care continuity.

Analysis of competitive behaviors among pharmaceutical, device, and digital entrants emphasizing collaboration, evidence generation, and manufacturing agility as differentiators

Competitive dynamics in the bronchial spasms treatment space reflect a blend of established pharmaceutical and device players, emerging specialty developers, and a growing cohort of digital health entrants. Incumbent firms with broad respiratory portfolios tend to leverage integrated capabilities-spanning formulation, device engineering, and global distribution-to sustain market presence, while smaller specialist companies focus on novel mechanisms or differentiated delivery technologies to carve niche positions. Collaboration between device and biologic developers has become more frequent, producing combination solutions that aim to improve adherence and clinical outcomes.

Strategic priorities among companies include strengthening clinical pipelines with targeted indications, investing in user-centric device design to reduce misuse, and generating robust real-world evidence to satisfy payer demands. Manufacturing agility and regulatory savvy are also competitive differentiators, as firms that can localize production, expedite regulatory submissions, and provide post-market safety data tend to achieve smoother market entry. Mergers, strategic partnerships, and licensing arrangements remain important mechanisms for accelerating access to complementary capabilities, while commercialization success often hinges on the depth of clinical stakeholder relationships and the ability to demonstrate measurable reductions in acute care episodes.

Concrete strategic actions for manufacturers and providers to strengthen supply resilience, drive adherence, generate compelling real-world evidence, and accelerate access

Industry leaders should prioritize a set of pragmatic actions that align clinical value with commercial resilience. First, diversify sourcing strategies for critical components and raw materials to reduce exposure to tariff-related and geostrategic disruptions, while evaluating opportunities for nearshoring or dual-sourcing to shorten lead times. Second, invest in device usability and adherence support tools, integrating objective adherence measures and patient education into product offerings to improve therapeutic outcomes and payer receptivity. Third, develop rigorous real-world evidence generation plans that capture clinically meaningful endpoints and health economic outcomes aligned with payer requirements to facilitate favorable access decisions.

Additionally, forge collaborative partnerships with healthcare systems and specialty clinics to streamline patient pathways and collect longitudinal outcome data that demonstrate value. Enhance regulatory engagement early to align clinical development with regional submission expectations, and consider staged rollouts that prioritize high-value care settings. Finally, adopt flexible pricing and contracting approaches, including outcome-based arrangements where appropriate, to lower payer barriers and accelerate adoption. Implementing these strategies will help organizations translate scientific advances into durable clinical impact and sustainable commercial performance.

Transparent description of multi-source research techniques combining clinician insights, literature synthesis, and cross-validated analysis to produce rigorous industry findings

The research approach underpinning this analysis combined qualitative and quantitative techniques to ensure balanced, multi-source insight into clinical practice, device adoption, payer behavior, and supply dynamics. Primary research included structured interviews with pulmonologists, respiratory nurses, procurement leaders, and reimbursement specialists to capture frontline perspectives on treatment selection, device usability, and access barriers. Secondary evidence was synthesized from peer-reviewed clinical literature, regulatory guidance documents, device performance specifications, and published clinical guidelines to contextualize primary findings and to validate mechanistic rationale.

Analytical rigor was achieved through cross-validation of themes across data sources, targeted case studies of representative product launches, and scenario-based analysis of supply chain and policy shocks. Limitations of the methodology are acknowledged: stakeholder interviews may reflect practice variation, and publicly available literature may lag the most recent commercial developments. To mitigate these constraints, the study applied conservative interpretation of emerging trends and prioritized triangulated findings that appeared consistently across independent sources. Where relevant, the research identifies evidence gaps and recommends follow-up primary studies to address critical uncertainties.

Concise synthesis of therapeutic, operational, and policy dynamics highlighting strategic priorities for converting innovation into clinical impact and commercial success

In summary, bronchial spasms treatment is undergoing a phase of substantive evolution driven by advances in targeted therapeutics, delivery technologies, and care delivery models. These shifts create opportunities to improve patient outcomes through better matching of therapeutic modality to phenotype, more reliable delivery through refined inhalation and nebulization systems, and enhanced adherence monitoring. At the same time, macro forces such as trade policy changes and regional regulatory heterogeneity require companies to be more deliberate in their manufacturing, sourcing, and market-entry strategies. Successful organizations will be those that combine clinical innovation with operational resilience and evidence generation tailored to payer expectations.

Decision-makers should view the current environment as one where coordinated investments across product design, clinical evidence programs, and supply chain architecture can yield competitive advantage. By aligning technical development with stakeholder needs and regional access dynamics, leaders can convert scientific promise into reproducible clinical benefit and sustainable commercial performance. The following call to action outlines options for acquiring the full report and arranging targeted briefings to translate these insights into immediate strategic plans.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth in biologic therapies targeting inflammatory pathways in bronchial spasms such as monoclonal antibodies
  • 5.2. Rising adoption of long-acting muscarinic antagonists for improved bronchial muscle relaxation in chronic obstructive airway diseases
  • 5.3. Emergence of digital inhaler devices with adherence monitoring and real time feedback to optimize bronchial spasm control
  • 5.4. Expansion of combination inhaler therapies with dual bronchodilators and corticosteroids to reduce exacerbations in bronchospastic conditions
  • 5.5. Increasing off label use of nebulized magnesium sulfate in emergency departments for acute bronchospasm management
  • 5.6. Development of novel nanoparticle based aerosol delivery systems for targeted bronchodilator therapy in bronchial spasms
  • 5.7. Rising demand among elderly patients for personalized bronchial spasm treatments with improved safety and tolerability profiles
  • 5.8. Regulatory approvals accelerating the launch of next generation biologics for severe uncontrolled asthma related bronchial spasms
  • 5.9. Impact of telemedicine platforms on remote monitoring and management of chronic bronchial spasm patients in underserved regions
  • 5.10. Advancements in biomarker driven and precision medicine approaches to customize bronchial spasm treatment regimens

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bronchial Spasms Treatment Market, by Treatment Type

  • 8.1. Inhalation Therapy
    • 8.1.1. Dry Powder Inhalers
      • 8.1.1.1. Multi-Dose Dpi
      • 8.1.1.2. Single-Dose Dpi
    • 8.1.2. Metered Dose Inhalers
    • 8.1.3. Nebulizers
      • 8.1.3.1. Jet Nebulizers
      • 8.1.3.2. Mesh Nebulizers
      • 8.1.3.3. Ultrasonic Nebulizers
  • 8.2. Injectable Medications
    • 8.2.1. Aminophylline
    • 8.2.2. Biologics
      • 8.2.2.1. Mepolizumab
      • 8.2.2.2. Omalizumab
      • 8.2.2.3. Reslizumab
    • 8.2.3. Systemic Steroids
  • 8.3. Oral Medications
    • 8.3.1. Anticholinergics
      • 8.3.1.1. Long-Acting Anticholinergics
      • 8.3.1.2. Short-Acting Anticholinergics
    • 8.3.2. Bronchodilators
      • 8.3.2.1. Long-Acting Beta Agonists
      • 8.3.2.2. Short-Acting Beta Agonists
    • 8.3.3. Combination Therapies
    • 8.3.4. Corticosteroids
      • 8.3.4.1. Inhaled Steroids
      • 8.3.4.2. Systemic Steroids

9. Bronchial Spasms Treatment Market, by Drug Class

  • 9.1. Anticholinergics
    • 9.1.1. Long-Acting Anticholinergics
    • 9.1.2. Short-Acting Anticholinergics
  • 9.2. Beta Agonists
    • 9.2.1. Long-Acting Beta Agonists
    • 9.2.2. Short-Acting Beta Agonists
  • 9.3. Corticosteroids
    • 9.3.1. Inhaled Corticosteroids
    • 9.3.2. Systemic Corticosteroids
  • 9.4. Leukotriene Modifiers
    • 9.4.1. Montelukast
    • 9.4.2. Zafirlukast
    • 9.4.3. Zileuton

10. Bronchial Spasms Treatment Market, by Route Of Administration

  • 10.1. Inhalation
    • 10.1.1. Aerosol
    • 10.1.2. Dry Powder
    • 10.1.3. Nebulization
  • 10.2. Injectable
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Oral
    • 10.3.1. Capsule
    • 10.3.2. Syrup
    • 10.3.3. Tablet
  • 10.4. Transdermal
    • 10.4.1. Gel
    • 10.4.2. Patch

11. Bronchial Spasms Treatment Market, by Distribution Channel

  • 11.1. Clinics
    • 11.1.1. Outpatient Clinics
    • 11.1.2. Specialist Clinics
  • 11.2. Hospital Pharmacies
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Online Pharmacies
    • 11.3.1. Hybrid
    • 11.3.2. Pure Play
  • 11.4. Retail Pharmacies
    • 11.4.1. Chain Pharmacies
    • 11.4.2. Independent Pharmacies

12. Bronchial Spasms Treatment Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
    • 12.2.1. Outpatient Clinics
    • 12.2.2. Specialist Clinics
  • 12.3. Home Care
  • 12.4. Hospitals
    • 12.4.1. Private Hospitals
    • 12.4.2. Public Hospitals

13. Bronchial Spasms Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bronchial Spasms Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bronchial Spasms Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. AstraZeneca plc
    • 16.3.3. Boehringer Ingelheim International GmbH
    • 16.3.4. Novartis AG
    • 16.3.5. Teva Pharmaceutical Industries Ltd.
    • 16.3.6. Sanofi S.A.
    • 16.3.7. Merck & Co., Inc.
    • 16.3.8. Viatris Inc.
    • 16.3.9. Cipla Limited
    • 16.3.10. Sumitomo Pharma Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRONCHIAL SPASMS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL BRONCHI